Patients | News | Contact About Us Management Team Board of Directors Scientific Founders Scientific Advisors Research Partners Our Science Scientific Platform CAR Technology TCR Technology Publications Pipeline Clinical Pre-Clinical Therapeutic Areas Investor Relations Stock Information News & Events Media SEC Filings Annual Reports Corporate Governance Investor FAQ Working at Juno Current Job Openings Our Viewpoints About Us Management Team Board of Directors Scientific Founders Scientific Advisors Research Partners Our Science Scientific Platform CAR Technology TCR Technology Publications Pipeline Clinical Pre-Clinical Therapeutic Areas Investor Relations Stock Information News & Events Media SEC Filings Annual Reports Corporate Governance Investor FAQ Working at Juno Current Job Openings Our Viewpoints Breakthrough Immunotherapies for Cancer Re-engaging the body’s immune system to treat cancer Overview Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer. Celgene and Juno Announce Ten-Year Collaboration https://www.junotherapeutics.com/wp-content/uploads/2015/06/Juno%20%2B%20Celgene_6.28_V4-HD.mp4 Our Science The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno’s technologies genetically engineer a patient’s own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. We use two different technologies to target cancer cells and activate T cells, CARs and TCRs. Juno Spotlights Jun 26 2015 Juno named to MIT Technology Review’s 50 Smartest Companies 2015 By Administrator | Home Page read more Juno’s Media Page Media Link Chimeric Antigen Receptors (CARs) Chimeric Antigen Receptor (CAR) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins. learn more T Cell Receptors (TCRs) High-affinity TCR technology provides T cells with a specific T cell receptor that recognizes cancer cells based on expression of specific proteins inside the cell or on the cell surface. learn more For Patients T cell immunotherapy using CAR and TCR technologies have shown promising results in early clinical trials and may offer new options for patients with cancer. learn more Contact 307 Westlake Avenue N., Suite 300 Seattle, WA 98109 206.582.1600 email inquiry Juno is Hiring Browse our Current Job Openings © 2015 Juno Therapeutics. All Rights Reserved Terms & Conditions